Filter posts

Orphan Drug Tax Credit is Crucial to Rare Disease R&D

The term “rare disease” may be misleading: to be “rare” a disease must effect fewer …

2015 FDA Approvals: Highest Levels in Over a Decade

2015 was a blockbuster year for FDA approvals of novel new medicines, many of them …

The March of Genetic Food Progress

You may already be familiar with Julie Kelly’s contributions to the Genetic Literacy Project but you may …

“Please Wait a Few Moments While Your Pill Prints”

Since the late 1980’s, innovators have dreamed of living in a world where science could …

Congress, Media Focused on Biotech Food Labeling

Media coverage of the biotech food labeling debate is at a fever pitch as the …

FDA Acts on Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …

Expanding the Role of Patients in Drug Development

Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to …

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From …

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …

New PhRMA Report: A Decade of Innovation in Rare Diseases

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released “A Decade of Innovation in …